The effect of lidocaine spray in reducing ophthalmic neuralgia in patients with multiple sclerosis

INTERVENTION: Intervention group : 10% lidocaine nasal spray, 2 puffs of the spray (equivalent to 0.2 mg) to be used during pain.. CONDITION: Multiple sclerosis. ; Multiple sclerosis PRIMARY OUTCOME: The primary outcome of the patient's pain intensity based on Visual Analogue Scale (VAS) criteria. Timepoint: Before using the spray. Method of measurement: These outcomes are measured by a neurologist based on the VAS. SECONDARY OUTCOME: Measurement of pain‐free time after each use of the spray?. Timepoint: The pain‐free period after using the spray during pain is recorded in 0‐6‐12‐24 hours and more than one week from the patients. Method of measurement: These outcomes are measured by the evaluator, who is a final year medical student who is not aware of the assignment of the subjects to each of the two allocation groups and the drugs used. Pain‐free time after using the spray during pain in hours 0‐6‐12‐24 and more than one week of patients are recorded. The instrument for measuring this variable is based on the patient's statements and its unit is amount of hours. INCLUSION CRITERIA: Definite MS confirmed by MRI Confirmation of ophthalmic neuralgia without response to drug treatment Performing a lidocaine sensitivity test and proving the absence of lidocaine sensitivity The patient's willingness to participate in the study and obtain informed consent The patient's MS must be of the relapsing remitting type and must have been approved by a neurologist.